Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Connecticut Mental Health Center, New Haven, Connecticut Johns Hopkins Bayview Medical Center, Baltimore, Maryland Israel
Hadassah Medical Center, Jerusalem Tel-Aviv Sourasky Medical Center (TASMC), Tel Aviv